Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 1;67(Pt 9):o2243-4.
doi: 10.1107/S1600536811030583. Epub 2011 Aug 6.

2-(5,6-Dihydro-benzimidazo[1,2-c]quinazolin-6-yl)phenol

2-(5,6-Dihydro-benzimidazo[1,2-c]quinazolin-6-yl)phenol

Naser Eltaher Eltayeb et al. Acta Crystallogr Sect E Struct Rep Online. .

Abstract

The asymmetric unit of the title compound, C(20)H(15)N(3)O, contains two independent mol-ecules, each of which is disordered over two sets of sites corresponding to a rotation of approximately 180° of the dihydro-benzimidazoquinazoline moiety, with refined site occupancies of 0.7479 (13) and 0.2521 (12) for both mol-ecules. The pyrimidine rings are in sofa conformations. In one mol-ecule, the hy-droxy-substituted benzene ring forms dihedral angles of 83.9 (3) and 82.4 (4)° for the major and minor components, respectively, with the mean plane of the benzimidazole ring system. The corres-ponding dihedral angles in the other mol-ecule are 88.31 (14) and 85.8 (6)°. In the crystal, mol-ecules are linked via inter-molecular O-H⋯N and N-H.·O hydrogen bonds into chains along [100].

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The molecular structure of the title compound showing 50% probability displacement ellipsoids for non-H atoms. All components are shown.
Fig. 2.
Fig. 2.
The molecular structure of the major component of molecule A showing 50% probability displacement ellipsoids for non-H atoms.
Fig. 3.
Fig. 3.
Part of the crystal structure of the title compound, viewed along the b axis. H atoms not involved in hydrogen bonds (dashed lines) have been omitted for clarity. Only the major disorder component is shown.

References

    1. Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). J. Chem. Soc. Perkin Trans. 2, pp. S1–19.
    1. Barreca, M. L., Chimirri, A., De Clercq, E., De Luca, L., Monforte, A.-M., Monforte, P., Rao, A. & Zappalà, M. (2003). Farmaco, 58, 259–263. - PubMed
    1. Bruker (2009). APEX2, SAINT and SADABS Bruker AXS Inc., Madison, Wisconsin, USA.
    1. Cremer, D. & Pople, J. A. (1975). J. Am. Chem. Soc. 97, 1354–1358.
    1. Demirayak, S., Abu Mohsen, U. & Cagri Karaburun, A. (2002). Eur. J. Med. Chem. 37, 255–260. - PubMed